Biotech stocks for your portfolio: Pulmatrix, In

Biotech stocks for your portfolio: Pulmatrix, Inc. (PULM), Celsion Corporation (CLSN)
By
Elbert Edwards -
February 10, 2017

Pulmatrix, Inc. (PULM) ended last trading session with a change of 0.41 percent. It trades at an average volume of 3.74M shares versus 4.13M shares recorded at the end of last trading session. The share price of $4.95 is at a distance of 886.06 percent from its 52-week low and down -29.08 percent versus its peak. The company has a market cap of $110.14M and currently has 22.25M shares outstanding. The share price is currently 104.8 percent versus its SMA20, 269.71 percent versus its SMA50, and 184.26 percent versus its SMA200. The stock has a weekly performance of -2.94 percent and is 738.98 percent year-to-date as of the recent close.

Feb. 3, 2017 — Pulmatrix, Inc., (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $3.33 million of shares of common stock in a registered direct offering.

Celsion Corporation (CLSN) recently recorded 32.86 percent change and currently at $0.49 is 68.97 percent away from its 52-week low and down -72.47 percent versus its peak. It has a past 5-day performance of 34.25 percent and trades at an average volume of 789.95K shares. The stock has a 1-month performance of 58.01 percent and is 61.24 percent year-to-date as of the recent close. There were about 30.32M shares outstanding which made its market cap $14.86M. The share price is currently 27.25 percent versus its SMA20, 8.93 percent versus its SMA50, and -53 percent versus its SMA200.

On Jan. 19, 2017 Celsion Corporation (CLSN) announced that it will present two posters at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from February 23 – 25, 2017 in Orlando, FL. The symposium will focus on the latest clinical and translational research in immuno-oncology and the implications for clinical care. The first poster will report clinical results from the Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. The second poster will report translational data from the OVATION Study and previous GEN-1 clinical trials. The posters will be presented by Khursheed Anwer, Ph.D., Celsion’s executive vice president and chief science officer.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!

Alway's searching for winners'